JPH11505850A - 代謝症候群および該症候群を含む病気の診断のための製剤 - Google Patents
代謝症候群および該症候群を含む病気の診断のための製剤Info
- Publication number
- JPH11505850A JPH11505850A JP8536000A JP53600096A JPH11505850A JP H11505850 A JPH11505850 A JP H11505850A JP 8536000 A JP8536000 A JP 8536000A JP 53600096 A JP53600096 A JP 53600096A JP H11505850 A JPH11505850 A JP H11505850A
- Authority
- JP
- Japan
- Prior art keywords
- cortisol
- novel use
- dexamethasone
- agonist
- metabolic syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Steroid Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Combined Controls Of Internal Combustion Engines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.代謝症候群、および、腹部肥満、老年性糖尿病、すなわちタイプIIの糖尿病 に発展する危険性の増加を伴うインシュリン分泌抵抗性、高血液脂肪、高血圧な どの関連する症状の診断のためのコルチソル作動薬診断システムの新規な使用法 。 2.上記コルチソル作動薬が、糖質コルチコイドおよび/または無機質コルチコ イド作用をもつ合成コルチソル類似体であることを特徴とする、請求項1に記載 の新規な使用法。 3.上記コルチソル作動薬がデキサメタゾーンであることを特徴とする、請求項 2に記載の新規な使用法。 4.上記デキサメタゾーンの投与量が0.05mgと0.5mgの間にあること を特徴とする、請求項3に記載の新規な使用法。 5.上記デキサメタゾーンの投与量が0.125mgと0.5mgの間にあるこ とを特徴とする、請求項4に記載の新規な使用法。 6.上記診断システムが、コルチソル作動薬の少なくとも二つの異なる投与量を 含むことを特徴とする、前記請求項のいずれか1項に記載の新規な使用法。 7.デキサメタゾーンの上記二つの投与量が0.125mgと0.5mgである ことを特徴とする、請求項6に記載の新規な使用法。 8.上記コルチソルの自己生成に対する抑制作用を測定する目的で、唾液中また は血清中のコルチソル含有量を測定する手段を含む、前記請求項のいずれか1項 に記載の新規な使用法。 9.上記診断システムが基礎コルチソル含有量を測定する手段を含む、請求項8 に記載の新規な使用法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9501991A SE505391C2 (sv) | 1995-05-30 | 1995-05-30 | Användning av kortisol-agonister för framställning av ett system för diagnostisering av det metabola syndromet |
SE9501991-5 | 1995-05-30 | ||
PCT/SE1996/000708 WO1996038179A1 (en) | 1995-05-30 | 1996-05-30 | Preparation for diagnostic of the metabolic syndrome and diseases including the syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11505850A true JPH11505850A (ja) | 1999-05-25 |
Family
ID=20398470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8536000A Ceased JPH11505850A (ja) | 1995-05-30 | 1996-05-30 | 代謝症候群および該症候群を含む病気の診断のための製剤 |
Country Status (16)
Country | Link |
---|---|
US (1) | US6410339B1 (ja) |
EP (1) | EP0835138B1 (ja) |
JP (1) | JPH11505850A (ja) |
CN (1) | CN1078479C (ja) |
AT (1) | ATE235258T1 (ja) |
AU (1) | AU716671B2 (ja) |
BR (1) | BR9608683A (ja) |
CA (1) | CA2222215A1 (ja) |
DE (1) | DE69626982T2 (ja) |
DK (1) | DK0835138T3 (ja) |
ES (1) | ES2189872T3 (ja) |
NO (1) | NO319829B1 (ja) |
PT (1) | PT835138E (ja) |
RU (1) | RU2171471C2 (ja) |
SE (1) | SE505391C2 (ja) |
WO (1) | WO1996038179A1 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7217505B2 (en) * | 1998-02-26 | 2007-05-15 | Cortendo Ab | Method for determining whether condition is symptom of metabolic syndrome |
SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
US20080200453A1 (en) | 2002-07-29 | 2008-08-21 | Cincotta Anthony H | Methods of treating metabolic syndrome using dopamine receptor agonists |
US20040220190A1 (en) * | 2002-07-29 | 2004-11-04 | Cincotta Anthony H. | Methods of treating metabolic syndrome using dopamine receptor agonists |
US9655865B2 (en) | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
US20040081678A1 (en) * | 2002-08-09 | 2004-04-29 | Anthony Cincotta | Therapeutic process for the treatment of obesity and associated metabolic disorders |
US8137993B2 (en) * | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
US8137994B2 (en) * | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
US20050215558A1 (en) * | 2004-03-25 | 2005-09-29 | Cincotta Anthony H | Methods of identifying responders to dopamine agonist therapy |
US20050232911A1 (en) * | 2004-04-19 | 2005-10-20 | Schreiber Brian D | Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid |
DE102004034640A1 (de) | 2004-07-16 | 2006-02-16 | Institut für Molekular- und Systemmedizin | Verfahren zur systemischen Biokorrektur eines Organismus |
US20090117660A1 (en) * | 2005-04-30 | 2009-05-07 | Oakville Hong Kong Co., Limited | Devices and methods for sample collection and analysis |
BRPI0717803A2 (pt) * | 2006-10-06 | 2013-11-19 | Nestec Sa | Composições e ensaios multiplicadores para a medição de mediadores biológicos de saúde fisiológica |
US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
RU2444298C1 (ru) * | 2010-07-15 | 2012-03-10 | Учреждение Российской академии медицинских наук Научный центр клинической и экспериментальной медицины Сибирского отделения РАМН (НЦКЭМ СО РАМН) | Способ диагностики метаболического синдрома |
CN105973881A (zh) * | 2016-04-27 | 2016-09-28 | 樊福好 | 一种检测机体活度的溶液及检测方法 |
-
1995
- 1995-05-30 SE SE9501991A patent/SE505391C2/sv not_active IP Right Cessation
-
1996
- 1996-05-30 AT AT96916423T patent/ATE235258T1/de not_active IP Right Cessation
- 1996-05-30 PT PT96916423T patent/PT835138E/pt unknown
- 1996-05-30 JP JP8536000A patent/JPH11505850A/ja not_active Ceased
- 1996-05-30 WO PCT/SE1996/000708 patent/WO1996038179A1/en active IP Right Grant
- 1996-05-30 BR BR9608683-1A patent/BR9608683A/pt not_active Application Discontinuation
- 1996-05-30 DE DE69626982T patent/DE69626982T2/de not_active Expired - Fee Related
- 1996-05-30 US US08/952,638 patent/US6410339B1/en not_active Expired - Fee Related
- 1996-05-30 RU RU97121292/14A patent/RU2171471C2/ru not_active IP Right Cessation
- 1996-05-30 EP EP96916423A patent/EP0835138B1/en not_active Expired - Lifetime
- 1996-05-30 ES ES96916423T patent/ES2189872T3/es not_active Expired - Lifetime
- 1996-05-30 CN CN96194229A patent/CN1078479C/zh not_active Expired - Fee Related
- 1996-05-30 DK DK96916423T patent/DK0835138T3/da active
- 1996-05-30 CA CA002222215A patent/CA2222215A1/en not_active Abandoned
- 1996-05-30 AU AU59173/96A patent/AU716671B2/en not_active Ceased
-
1997
- 1997-11-28 NO NO19975492A patent/NO319829B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
SE9501991L (sv) | 1996-12-01 |
WO1996038179A1 (en) | 1996-12-05 |
MX9709234A (es) | 1998-10-31 |
NO319829B1 (no) | 2005-09-19 |
DE69626982T2 (de) | 2004-03-04 |
CA2222215A1 (en) | 1996-12-05 |
DE69626982D1 (de) | 2003-04-30 |
CN1078479C (zh) | 2002-01-30 |
SE9501991D0 (sv) | 1995-05-30 |
CN1185743A (zh) | 1998-06-24 |
EP0835138A1 (en) | 1998-04-15 |
SE505391C2 (sv) | 1997-08-18 |
ATE235258T1 (de) | 2003-04-15 |
US6410339B1 (en) | 2002-06-25 |
NO975492D0 (no) | 1997-11-28 |
DK0835138T3 (da) | 2003-07-21 |
BR9608683A (pt) | 1999-12-07 |
NO975492L (no) | 1998-01-27 |
PT835138E (pt) | 2003-08-29 |
AU5917396A (en) | 1996-12-18 |
ES2189872T3 (es) | 2003-07-16 |
EP0835138B1 (en) | 2003-03-26 |
AU716671B2 (en) | 2000-03-02 |
RU2171471C2 (ru) | 2001-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11505850A (ja) | 代謝症候群および該症候群を含む病気の診断のための製剤 | |
Pasquali et al. | Body fat distribution has weight-independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome | |
Mårin et al. | Cortisol secretion in relation to body fat distribution in obese premenopausal women | |
Waltman et al. | Spontaneous and glucocorticoid-inhibited adrenocorticotropic hormone and cortisol secretion are similar in healthy young and old men | |
Belmaker et al. | Human platelet monoamine oxidase changes during the menstrual cycle | |
Ghosh et al. | Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis | |
Lester et al. | Symptom fluctuation in bulimia nervosa: relation to menstrual-cycle phase and cortisol levels | |
Houdeau et al. | Sex steroid regulation of macrophage migration inhibitory factor in normal and inflamed colon in the female rat | |
Falsetti et al. | Treatment of moderate and severe hirsutism by gonadotropin-releasing hormone agonists in women with polycystic ovary syndrome and idiopathic hirsutism | |
Dundar et al. | Leptin levels in boys with pubertal gynecomastia | |
Kekkonen et al. | Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception | |
Oncken et al. | Effects of smoking cessation or reduction on hormone profiles and bone turnover in postmenopausal women | |
Brown et al. | Effect of metoclopramide on the secretion and metabolism of aldosterone in man | |
Moe et al. | Growth hormone in postmenopausal women after long-term oral estrogen replacement therapy | |
Reame et al. | Pulsatile LH secretion in women with premenstrual syndrome (PMS): evidence for normal neuroregulation of the menstrual cycle | |
Chidakel et al. | High prevalence of adrenal suppression during acute illness in hospitalized patients receiving megestrol acetate | |
Wolthers | Methodological aspects of short-term knemometry in the assessment of exogenous glucocorticosteroid-induced growth suppression in children | |
Małgorzewicz et al. | Influence of body mass on kidney graft function in patients after kidney transplantation | |
US5550029A (en) | Method for diagnosing estrogen responsiveness | |
Demir et al. | New anthropometric measurements: Relationship to thyroid functions in euthyroid obese subjects | |
Tourniaire et al. | The 24-h cortisol secretory pattern in Cushing’s syndrome | |
Ulutaş et al. | The association between triglycerides/high-density lipoprotein cholesterol ratio, insulin resistance, and serum androgen levels in patients with polycystic ovary syndrome | |
Negus et al. | Sex differences in thermal nociception and prostaglandin-induced thermal hypersensitivity in rhesus monkeys | |
Sabbadin et al. | Long-Lasting Effects of Spironolactone After its Withdrawal in Patients with Hyperandrogenic Skin Disorders | |
Brambilla et al. | Neurotransmitter and hormonal background of hostility in anorexia nervosa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050308 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050607 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050715 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050908 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070515 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20071003 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071127 |